Some patients with low-level viremia (LLV) are also likely to develop hepatocellular carcinoma (HCC) or other liver diseases. The relationship between HBV RNA levels and fibrosis in patients with HBV DNA negative or LLV is still lacking evidence. The purpose of this study is to observe the differences in HBV RNA levels and their association with efficacy in HBV DNA negative or LLV patients. Investigators conduct the prospective, single-center, non-randomized, observational clinical study. A total of 100 chronic hepatitis B (CHB) patients who receive antiviral therapy with nucleoside (acid) analogues for 1-3 years will be enrolled. The enrolled patients will be followed up five times to collect clinical data and record adverse events (at baseline, week 12, week 24, week 36 and week 48, respectively).
Study Type
OBSERVATIONAL
Enrollment
100
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The decrease of HBV RNA from baseline to 48 weeks
The investigators detect the dynamic change of HBV RNA and the decline from baseline to 48 weeks;
Time frame: 2023.8-2025.8
HBV RNA undetectable rate at 48 weeks;
After 48 weeks of treatment after enrollment, the investigators detect the HBV RNA undetectable rate 48 weeks;
Time frame: 2023.8-2025.8
The association of the dynamic changes of serum HBV RNA levels with HBsAg and HBeAg levels;
During 48 weeks of treatment, the investigators detect the association of the dynamic changes of serum HBV RNA levels with HBsAg and HBeAg levels;
Time frame: 2023.8-2025.8
The association of HBV RNA changes with the liver stiffness;
During 48 weeks of treatment, the investigators detect the association of HBV RNA changes with the liver stiffness;
Time frame: 2023.8-2025.8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.